Patents by Inventor David Presky

David Presky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-BAFF antibodies
    Patent number: 11370818
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 28, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith A. Canada, Michael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John J. Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
  • NOVEL ANTI-BAFF ANTIBODIES
    Publication number: 20190309034
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 10, 2019
    Inventors: Scott Ronald BRODEUR, Keith A. CANADA, Michael DZIEGELEWSKI, Philip Nicholas GORMAN, Pankaj GUPTA, Ashraf KHALIL, John J. MIGLIETTA, Amy Marie NICOLETTI, Qi PAN, David PRESKY, Sanjaya SINGH, Tao WU, Haiguang XIAO
  • Anti-BAFF antibodies
    Patent number: 10377804
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: August 13, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith A. Canada, Michael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John J. Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
  • NOVEL ANTI-BAFF ANTIBODIES
    Publication number: 20180127474
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: November 6, 2017
    Publication date: May 10, 2018
    Inventors: Scott Ronald BRODEUR, Keith A. CANADA, Michael DZIEGELEWSKI, Philip Nicholas GORMAN, Pankaj GUPTA, Ashraf KHALIL, John J. MIGLIETTA, Amy Marie NICOLETTI, Qi PAN, David PRESKY, Sanjaya SINGH, Tao WU, Haiguang XIAO
  • Anti-BAFF antibodies
    Patent number: 9840543
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: December 12, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith Canada, Mlchael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John James Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
  • NOVEL ANTI-BAFF ANTIBODIES
    Publication number: 20150218267
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: January 30, 2015
    Publication date: August 6, 2015
    Inventors: Scott Ronald BRODEUR, Keith CANADA, MIchael DZIEGELEWSKI, Philip Nicholas GORMAN, Pankaj GUPTA, Ashraf KHALIL, John James MIGLIETTA, Amy Marie NICOLETTI, Qi PAN, David PRESKY, Sanjaya SINGH, Tao WU, Haiguang Xiao
  • Antibodies against human IL-12
    Publication number: 20050281823
    Abstract: The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human IL-12 p75 heterodimer, but do not bind to the p40 subunit alone. The heterodimer specific IL-12 antibodies neutralize rhesus monkey IL-12 bioactivity with a potency similar to their potency for neutralizing human IL-12 bioactivity making them useful IL-12 antagonists for in vivo studies in the rhesus monkey.
    Type: Application
    Filed: July 19, 2005
    Publication date: December 22, 2005
    Inventors: Maurice Gately, David Presky